Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05371223 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases(Nab-PIPAC) | unknown | Phase 2 | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER |
| 1 |
| Feb 26, 2024 |
| clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05930665 | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05135715 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | unknown | Phase 2 | 50 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06066255 | PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM(CASPER) | unknown | Phase 2 | 27 | Institut Paoli-CalmettesOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06238245 | Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade | unknown | Phase 2 | 22 | Beijing 302 HospitalOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255847 | Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | unknown | Phase 2 | 43 | Shanxi Bethune HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05163249 | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC(FLOWERS) | unknown | Phase 2 | 44 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03599960 | Combination Chemotherapy in Patients With Newly Diagnosed BPDCN(LpDessai) | unknown | Phase 2 | 26 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05875428 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT01871454 | Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers | unknown | Phase 2 | 59 | University of LouisvilleOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03549273 | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | unknown | Phase 2 | 62 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06238336 | Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours | unknown | Phase 2 / Phase 3 | 30 | Shanxi Bethune HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06235918 | Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Xiang LuOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02840409 | Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | unknown | Phase 2 | 109 | The Hospital for Sick ChildrenOTHER | 4 | Jan 31, 2024 | clinicaltrials |
| NCT05478993 | Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement(SPODUMENE) | unknown | Phase 2 | 21 | Peking University People's HospitalOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05489926 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | unknown | Phase 2 | 15 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06223646 | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 29 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06224842 | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | unknown | Phase 1 / Phase 2 | 30 | Huijing WuOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 51 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06217003 | Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Jan 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2024source: clinicaltrials